Compugen Reports Second Quarter 2026 Results

Data ReadoutCOM701Neutral

AI Analysis

Summary

Compugen reported Q2 2026 results with the MAIA-ovarian trial for COM701 progressing as planned, with median progression-free survival interim data expected in Q1 2027. A trial-in-progress poster on MAIA-ovarian was presented at ESMO Gynaecological Cancers Congress 2026.

Clinical Trial Data

Outcome Details

Median progression-free survival data from interim analysis expected by Q1 2027

Importance:5/10

Sentiment:

0.20

oncologyovarian cancerPhase 2/3MAIA-ovarianinterim analysisprogression-free survivalESMO Congress

Related Companies

$CGEN

Read the original article

Published by PR Newswire Clinical Trials on August 3, 2026 11:00 AM

Read Original